Title of article :
Venom allergy treatment practices in Poland in comparison to guidelines: next edition of the national audit
Author/Authors :
Cichocka-Jarosz, Ewa Department of Paediatrics - Jagiellonian University Medical College, Krakow, Poland , Stobiecki, Marcin Department of Clinical and Environmental Allergology - Jagiellonian University Medical College, Krakow, Poland , Nittner-Marszalska, Marita Department of Internal Disease and Allergology - Medical University of Wroclaw, Poland , Jedynak-Wąsowicz, Urszula Department of Paediatrics - Jagiellonian University Medical College, Krakow, Poland , Brzyski, Piotr Dziupla Statistical Analysis, Krakow, Poland
Abstract :
Introduction
Venom immunotherapy treatment (VIT) is the only causal treatment of hymenoptera venom anaphylaxis, which aims to provide long-lasting immunoprotection against severe reactions to subsequent stings.
Aim
To reassess the compliance of VIT procedures in the Polish allergy centres with the European guidelines.
Material and methods
A structured questionnaire survey conducted in all 33 VIT-centres. The response rate was 94%.
Results
The ultrarush initial protocol was the most common protocol (71%, n = 22), usually lasting for 3.5 h (50%, n = 7). The most frequent (36%, n = 11) time interval from the initial to the first maintenance dose (MD) was 14 days, ranging from 7 to 35 days. All centres used an MD of 100 μg. The most frequent time interval between subsequent MDs was 4 weeks (58%, n = 18). Five years’ of VIT was declared by 71% (n = 22). Before the termination of treatment, more than half of the centres (58%, n = 18) performed sIgE and almost half (42%, n = 13) performed skin tests. To confirm VIT efficacy, few centres (26%, n = 8) conducted the sting challenge. About half of centres provided the patients with an adrenalin auto-injector both at the time of initial diagnostics and at the end of treatment. More than half (55%, n = 17) used antihistamines in all patients. Almost half (45%, n = 14) declared to stop treatment with β-blockers and almost one fourth (23%, n = 7) discontinued angiotensin-converting-enzyme inhibitors.
Conclusions
In the most important procedures, there is a very high compliance with the guidelines. In the areas where the guidelines are not precise, we observed a large spread of results.
Keywords :
venom allergy , immunotherapy , national survey
Journal title :
Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii